Greg Lucier, Mark Stevenson, David Hoffmeister, Tony White, Michael Egholm, Jason Affourtit, Brian Desany, David Bentley, Sean Humphray, Tony Cox, Scott Kahn, Keira Cheetham, Francisco De La Vega, Clarence Lee, Gina Costa, Kevin McKernan, Fiona Hyland, He | GenomeWeb
Greg Lucier, chairman, president, and CEO of Invitrogen, will become CEO of Applied Biosystems following Invitrogen’s planned acquisition of the company.  
Mark Stevenson, president and chief operating officer of ABI, will retain that role in the new company.
David Hoffmeister, senior vice president of finance and chief financial officer of Invitrogen, will remain CFO of the new ABI.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.